[1] HE Y, LIU G, ZHUO X, et al.Clinical Characteristics and Prognosis of Paediatric Respiratory Syncytial Virus-related Encephalopathy[J]. Italian Journal of Pediatrics, 2024, 50(1): 134. [2] NAYLOR J, HO A, SOIZA RL. Why the UK is Vaccinating Its Older Adult Population against RSV-What Geriatricians Should Know[J]. Age and Ageing, 2024, 53(9): afae202. [3] DREW L.Will a New Wave of RSV Vaccines Stop the Dangerous Virus?[J]. Nature, 2023, 614(7946): 20. [4] YANG L, XIAO XJ, ZHU CP, et al.Epidemiological Characteristics of Respiratory Syncytial Virus Infection in Preschool Children and Risk Factors for Severe Pneumonia[J]. Chinese Journal of Experimental and Clinical Virology(中华实验和临床病毒学杂志), 2024, 38(3): 263-268. [5] YOO JK, KIM TS, HUFFORD MM, et al.Viral Infection of the Lung: Host Response and Sequelae[J]. Journal of Allergy and Clinical Immunology, 2013, 132(6): 1263-1276. [6] HAO W, ZHU X, LIU Z, et al.Aluminum Exposure Induces Central Nervous System Impairment via Activating NLRP3-Medicated Pyroptosis Pathway[J]. Ecotoxicology and Environmental Safety, 2023, 264: 115401. [7] CHOUDHURY SM, MA X, ABDULLAH SW, et al.Activation and Inhibition of the NLRP3 Inflammasome by RNA Viruses[J]. Journal of Inflammation Research, 2021, 14: 1145-1163. [8] SHEN C, ZHANG Z, XIE T, et al.Rhein Suppresses Lung Inflammatory Injury Induced by Human Respiratory Syncytial Virus through Inhibiting NLRP3 Inflammasome Activation via NF-κB Pathway in Mice[J]. Frontiers in Pharmacology, 2020, 10: 1600. [9] ZHU Q, PAN J, XU J, et al.Research Progress on Shufeng Jiedu Capsules in Treatment of Respiratory Infectious Diseases[J]. Chinese Traditional and Herbal Drugs(中草药), 2022, 53(11): 3557-3563. [10] ZHOU F, ZHAO GZ, LI B, et al.Systematic Review and Meta-Analysis of Efficacy and Safety of Shufeng Jiedu Capsules in Treatment of Influenza[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2023, 48(22): 6216-6224. [11] QIU H, LI ZX, ZHU TN, et al.in-vivo Experimental Research of Antiviral Action of Shufeng Jiedu Capsule[J]. Traditional Chinese Drug Research and Clinical Pharmacology(中药新药与临床药理), 2014, 25(1): 14-17. [12] XU Y, BAO L, ZHAO R.Mechanisms of Shufeng Jiedu Capsule in Treating Bacterial Pneumonia Based on Network Pharmacology and Experimental Verification[J]. Chinese Herbal Medicines(中草药), 2024, 16(4): 656-666. [13] HAN Y, XU J, ZHU Q, et al. Study on Basic and Clinical Application of Shufeng Jiedu Capsule in Treating Respiratory Tract Infection[J]. Chinese Medical Journal(中华医学杂志), 2023, 25, 18(1): 45. [14] CAO S, PANG B, XU YL, et al.Effects of Shufeng Jiedu Capsules Prophylactic Administration on TLR4-Mediated Inflammatory Injury in Lung Tissue in a Mouse Model of Influenza Virus Infection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(1): 45-50. [15] BAO L, GENG ZH, CUI XL. Shufengjiedu Capsule Regulates TLR4/TRIF/TBK1 Signaling Pathway to Improve Lung Inflammation in Mice Infected with Human Coronavirus 229E[J/OL]. Chinese Journal of Experimental Traditional Medical Formulae (中国实验方剂学杂志),(2025-01-15)[2025-03-24]. https://doi.org/10.13422/j.cnki.syfjx.20242345. [16] BEM RA, KNEYBER MC, VAN WOENSEL JB.Respiratory Syncytial Virus-induced Paediatric ARDS: Why We should Unpack the Syndrome[J]. The Lancet Respiratory Medicine, 2017, 5(1): 9-10. [17] BACHMANN DC, PFENNINGER J.Respiratory Syncytial Virus Triggered Adult Respiratory Distress Syndrome in Infants: a Report of Two Cases[J]. Intensive Care Medicine, 1994, 20(1): 61-63. [18] FLERLAGE T, CRAWFORD JC, ALLEN EK, et al.Single Cell Transcriptomics Identifies Distinct Profiles in Pediatric Acute Respiratory Distress Syndrome[J]. Nature Communications, 2023, 14(1): 3870. [19] RAVINDRANATH TM, GOMEZ A, HARWAYNE-GIDANSKY I, et al.Pediatric Acute Respiratory Distress Syndrome Associated with Human Metapneumovirus and Respiratory Syncytial Virus[J]. Pediatric Pulmonology, 2018, 53(7): 929-935. [20] Pharmacopoeia Commission of the People’s Republic of China. Pharmacopoeia of the People's Republic of China: Volume I(中华人民共和国药典: 一部)[M]. Beijing: China Medical Science Press, 2020. [21] LU CL, YANG LQ, JIN XY, et al.Chinese Herbal Medicine Shufeng Jiedu Capsule for Mild to Moderate COVID-19: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial[J]. Front Pharmacol, 2024, 15: 1383831. [22] KIM TH, LEE HK.Innate Immune Recognition of Respiratory Syncytial Virus Infection[J]. BMB Reports, 2014, 47(4): 184-191. [23] XU DW, TATE MD.Taking AIM at Influenza: the Role of the AIM2 Inflammasome[J]. Viruses, 2024, 16(10): 1535. [24] CASE CL.Regulating Caspase-1 during Infection: Roles of NLRs, AIM2, and ASC[J]. Yale Journal of Biology and Medicine, 2011, 84(4): 333-343. [25] FRANCHI L, EIGENBROD T, MUNOZ-PLANILLO R, et al.The Inflammasome: a Caspase-1-Activation Platform that Regulates Immune Responses and Disease Pathogenesis[J]. Nature Immunology, 2009, 10(3): 241-247. [26] WALDSTEIN KA, VARGA SM.Respiratory Viruses and the Inflammasome: the Double-Edged Sword of Inflammation[J]. PLoS Pathogens, 2022, 18(12): e1011014. [27] HARKER JA, GODLEE A, WAHLSTEN JL, et al.Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells[J]. Journal of Virology, 2010, 84(8): 4073-4082. [28] RUSSELL CD, UNGER SA, WALTON M, et al.The Human Immune Response to Respiratory Syncytial Virus Infection[J]. Clinical Microbiology Reviews, 2017, 30(2): 481-502. [29] CHAVEZ-BUENO S, MEJIAS A, GOMEZ AM, et al.Respiratory Syncytial Virus-Induced Acute and Chronic Airway Disease is Independent of Genetic Background: an Experimental Murine Model[J]. Virology Journal, 2005, 2: 46. [30] CANTU-FLORES K, RIVERA-ALFARO G, MUNOZ-ESCALANTE JC, et al.Global Distribution of Respiratory Syncytial Virus A and B Infections: a Systematic Review[J]. Pathog Glob Health, 2022, 116(7): 398-409. [31] MESSINA E, DANISE A, FERRARI G, et al.Ribavirin Aerosol in the Treatment of SARS-CoV-2: a Case Series[J]. Infectious Diseases and Therapy, 2021, 10(4): 2791-2804. [32] TEJADA S, MARTINEZ-REVIEJO R, KARAKOC HN, et al.Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: a Systematic Review and Meta-Analysis[J]. Advances In Therapy, 2022, 39(9): 4037-4051. |